ZBH

Business Context and Reporting Period

Company: Zimmer Biomet Holdings, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025 (Q3 2025)
Business Overview: Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive products, sports medicine, biologics, extremities, trauma, craniomaxillofacial, and thoracic products, as well as digital and robotic technologies. The company operates through three reportable segments: Americas, EMEA, and Asia Pacific.

Key Financial Metrics

Note: Total Debt calculated as Current portion of long-term debt ($600.0M) + Long-term debt ($7,512.6M) as of Sept 30, 2025.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 9.7% in Q3 and 5.9% for the nine months ended Sept 30, 2025, compared to the prior year. Growth was driven by the Paragon 28 acquisition (contributing 3.6% in Q3), market growth, and new product introductions.
• Earnings Decline: Net earnings decreased 7.3% in Q3 and 14.8% for the nine months. This was primarily due to a one-time tax benefit in the prior year (2024), higher acquisition-related costs for Paragon 28, increased interest expense from new borrowings, and investments in direct-to-patient marketing and IT.
• Acquisition Impact: The company completed the acquisition of Paragon 28, Inc. in April 2025 for approximately $1.24 billion in initial consideration. This significantly impacted intangible asset amortization and operating expenses.
• Debt Structure: Total debt increased significantly due to new issuances (Swiss Notes, 2027/2030/2035 Senior Notes) to fund the Paragon 28 acquisition and redeem maturing 2025 notes. Interest expense, net, increased to $75.4M in Q3 2025 from $54.3M in Q3 2024.
• Restructuring: Restructuring and cost reduction expenses decreased to $21.4M in Q3 2025 from $32.2M in Q3 2024, reflecting the timing of the 2025 Restructuring Plan versus the larger 2023 plan.

Guidance, Outlook, and Risks

• 2025 Outlook: Management expects full-year 2025 revenue growth of 6.7% to 7.7%. Net earnings are expected to decrease compared to 2024 due to higher acquisition costs, operating expenses, intangible amortization, manufacturing costs (inflation/tariffs), and a higher effective tax rate.
• Tariff Impact: The company anticipates recognizing approximately $40 million in additional expenses related to tariffs in full-year 2025.
• Subsequent Event: On October 7, 2025, the company completed the acquisition of Monogram Technologies Inc. for approximately $180 million in initial consideration, with up to $570 million in potential contingent value rights.
• Key Risks:
  • Tax Disputes: Ongoing disputes with the IRS regarding tax years 2013-2019 could result in material tax expense (e.g., proposed adjustment for 2016-2019 could add ~$312M in tax expense).
  • Integration: Risks associated with successfully integrating Paragon 28 and Monogram Technologies.
  • Legal: Accrued litigation liabilities were $146.6 million as of Sept 30, 2025, with potential for material adverse impact if estimates change.
  • Regulatory: Compliance with EU Medical Device Regulations and FDA requirements.

Investor Verification Checklist

• Acquisition Synergies: Verify the integration progress and revenue contribution of Paragon 28 and the newly acquired Monogram Technologies against management's growth targets.
• Tax Liability Exposure: Review the status of IRS audits for tax years 2013-2019 and the potential financial impact of the proposed $312 million adjustment.
• Debt Servicing: Assess the impact of increased interest rates and higher debt balances on future cash flows and the ability to meet the 4.5x debt-to-EBITDA covenant.
• Tariff Mitigation: Evaluate the company's ability to pass on tariff costs to customers versus absorbing them, specifically regarding the projected $40 million expense.
• Restructuring Savings: Monitor the realization of cost savings from the 2019, 2023, and 2025 restructuring plans to ensure they offset increased operating expenses.